SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biochem Pharma (BCHE)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: JDN who wrote (769)9/18/2000 9:02:38 PM
From: Spekulatius   of 783
 
I own some BCHE as a LT investment. The problem right now, is that analysts have lowered their earning estimates for Y2001, obviously due to weak AZT sales. Management has explained the decreasing AZT revenues with nonreoccurring order from Brasil but sales have been weak worldwide and Zeffix sales are too small to make much of a dent right now.
The big issue with BCHE (as with all other biotechs) is if their late stage pipeline comes through. IMHO, we need positive PhIII results from a drug candidate to move this stock.I still think that BCHE is a good LT investment at current prices but I do not see a large short term potential.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News